Neurosurgical Equipment (Global Market)

Neurosurgical equipment is a group of special tools designed to carry out diagnostic and surgical interventions on the central and peripheral nervous systems.

Pre-operative examination of patients based on the use of interventional neurorengenology technologies allows us to determine with high accuracy the treatment method that will be the most effective and safest for the patient. With the help of modern neurosurgical equipment, brain operations are carried out much more efficiently and with the greatest caution.

Types of neurosurgical instruments

Data Bridge Market Research analysts divide neurosurgical tools into the following rates:

• solutions for endovascular helical embolization;
• angioplasty devices (carotid artery stents and embolic protection systems);
• tools for maintaining life support during microsurgical interventions (microconductors and microcatheters);
• thrombus removal devices (thrombectomy).

Depending on the type of operations, neurosurgical equipment is divided into tools for:

• embolization;
• angioplasty;
• thrombectomy.

2024

Global Neurosurgical Equipment Market Size Reaches $12.83 Billion for the Year

In 2024, sales of neurosurgical equipment on a global scale amounted to $12.83 billion. The North American region accounted for almost 40% of global costs. Such data are given in the review of Grand View Research, which Zdrav.Expert got acquainted with in mid-May 2025.

The study looks at surgical as well as diagnostic and therapeutic neurological devices. One of the main drivers of the analytics market is the growing prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease and epilepsy. According to the World Health Organization (WHO), in 2021, about 57 million people worldwide suffered from dementia, 60-70% of whom had Alzheimer's disease. The number of people with dementia could rise to 78m by 2030 and exceed 139m by 2050. In addition, worldwide there has been a rapid increase in disability and mortality as a result of Parkinson's disease. In 2019, the number of people suffering from this ailment exceeded 8.5 million people, and the prevalence of Parkinson's disease has doubled in 25 years. Plus, an increasing burden of depression among people of various age groups is recorded.

The observed trends lead to an increase in demand for neurostimulation devices such as transcranial magnetic stimulation (TMS) implants, vagus nerve stimulation (VNS) and deep brain stimulation (DBS). In particular, TMS products can be used for the treatment of depression, Parkinson's disease, epilepsy, auditory hallucinations in schizophrenia, obsessive-compulsive disorder, amyotrophic lateral sclerosis, etc. In turn, VNS therapy is aimed at treating epilepsy. The DBS method is used in the therapy of Parkinson's disease, cervical dystonia, essential tremor, etc.

The government funding for research into neurological disorders to improve treatment and care has a positive impact on the market in question. Such ailments lead to increased spending at the level of states, local communities, families and individuals, as well as economic damage due to reduced labor productivity. Supporting the industry at the government level promotes the development of advanced products and systems. Technological advances play an important role in the development of the market, including the introduction of artificial intelligence and remote patient monitoring platforms, the creation of miniature implantable devices and new type of wireless products.

In 2024, as stated in the study, the neurostimulation segment provided 54.59% of total revenue. The remaining part of the expenses fell on the decisions of interventional neurology, neurosurgical equipment, etc. From a geographical point of view, North America leads with a share of 39.7% of global sales. Significant players on a global scale are:

• Medtronic;
• Johnson and Johnson Services;
• Penumbra;
• Microport Scientific Corporation;
• Stryker;
• Microvention Inc ( Terumo Corporation);
• Codman Neuro ( Integra Lifesciences );
• Abbott;
• Boston Scientific;
• Nexstim;
• LivaNova;
• Neuropace;
• electroCore;
• Axonics;
• Söring;
• CooperSurgical;
• Zimmer Biomet;
• Brain lab;
• Acandis.

Analysts at Grand View Research believe that in the future, the CAGR in the market under consideration will be 8.9%. As a result, in 2025 the costs will amount to $13.9 billion, and by 2030 they will rise to $21.28 billion.^[1]

World's first laser neurosurgery device that doesn't need cooling released

On January 24, 2024, ClearPoint Neuro unveiled a laser system called Prism designed for neurosurgery. It is said to be the world's first device in its class that does not require cooling. Read more here.

2016: Market size of $1.85 billion

In 2016, the global market for neurosurgical instruments reached $1.85 billion, according to Data Bridge Market Research.

According to analysts, sales of this equipment in the period from 2017 to 2024 will grow by 8.9% per year and will reach $3.66 billion by the end of this period of time.

The neurosurgical equipment market was estimated at $1.85 billion in 2016

Experts call the main drivers of the market under consideration technological progress, an increase in the number of the elderly population and overweight people, the growing popularity of non-invasive methods and an increase in the frequency of hemorrhagic and ischemic stroke.

Specialists consider the lack of highly qualified neurologists and strict administrative restrictions to be the main problems for the market.

The following companies are called the largest manufacturers of neurosurgical equipment in Data Bridge Market Research:

• Medtronic;
• Stryker;
• Terumo;
• Penumbra;
• Covidien;
• Abbott;
• Merit Medical Systems;
• Johnson & Johnson;
• W. L. Gore & Associates;
• Bayer AG;
• MicroPort Scientific;
• Medikitco;
• UreSil;
• Boston Scientific;
• Sequent Medical.^[2]

Notes